Copyright
©The Author(s) 2021.
World J Clin Oncol. Jun 24, 2021; 12(6): 404-428
Published online Jun 24, 2021. doi: 10.5306/wjco.v12.i6.404
Published online Jun 24, 2021. doi: 10.5306/wjco.v12.i6.404
Table 2 Effect of metronomic chemotherapy targeting muscarinic acetylcholine receptors on breast tumors
Murine breast malignant cells | Murine breast not malignant cells |
Paclitaxel (10-11 mol/L) + Carbachol (10-9 mol/L)[126] | |
LM2: 68.2 ± 5.1b | NMuMG: 6.8 ± 6.6 |
LM3: 64.6 ± 6.5b | |
Human breast malignant cells | Human breast not malignant cells |
Paclitaxel (10-9 mol/L) + Carbachol (10-11 mol/L)[127] | |
MCF-7: 45.6 ± 5.8a | MCF-10A: 1.9 ± 0.3 |
Paclitaxel (10-9 mol/L) + Carbachol (10-10 mol/L)[128] | |
MDA-MB468: 33.4 ± 2.5c | MCF-10A: 2.9 ± 3.1 |
Paclitaxel (10-9 mol/L) + Arecaidine propargyl ester (10-7 mol/L)[128] | |
MDA-MB468: 26.9 ± 3.6c | MCF-10A: 3.3 ± 6.2 |
Paclitaxel (10-8 mol/L) + Carbachol (10-11 mol/L)[128] | |
MDA-MB231: 36.8 ± 6.2c | MCF-10A: 3.1 ± 6.2 |
Doxorubicin (10-8 mol/L) + Carbachol (10-11 mol/L)[128] | |
MDA-MB231: 35.3 ± 0.8c | MCF-10A: 6.1 ± 3.1 |
Paclitaxel (10-8 mol/L) + Arecaidine propargyl ester (10-5 mol/L)[128] | |
MDA-MB231: 35.8 ± 3.1c | MCF-10A: 8.2 ± 6.5 |
Doxorubicin (10-8 mol/L) + Arecaidine propargyl ester (10-5 mol/L)[128] | |
MDA-MB231: 33.3 ± 2.1c | MCF-10A: 7.8 ± 6.8 |
Paclitaxel (10-6 mol/L)[128] | |
MDA-MB231: 38.0 ± 6.1c | MCF-10A: 33.3 ± 1.5c |
Doxorubicin (10-6 mol/L)[128] | |
MDA-MB231: 41.1 ± 2.3c | MCF-10A: 45.7 ± 1.8c |
- Citation: Español A, Salem A, Sanchez Y, Sales ME. Breast cancer: Muscarinic receptors as new targets for tumor therapy. World J Clin Oncol 2021; 12(6): 404-428
- URL: https://www.wjgnet.com/2218-4333/full/v12/i6/404.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i6.404